26 Jan 2020

Hello reader!

It's quite unusual for us to write more than once a month. But it just seems appropriate to intervene as market dynamics for the near-term appears to be shifting fast.

Last weekend, we had written about the higher probability for the final two weeks of January to turn out more volatile, particularly for the healthcare sector. Since then, two new risk elements have emerged: (a) the unrelenting spread of Coronavirus with both health and economic implications, and (b) a surge in the candidacy of Senator Berne Sanders, who has an aggressive healthcare plan. The first one affects the broader market, while the second one specifically healthcare.

Keeping this in mind, we are reducing the model portfolio exposure. 

_____________________

Closing 

ASMB     Assembly Biosciences

_____________________

The total positions in the model portfolio after this transaction will be 7 or 70% invested. The portfolio will be reassessed at month-end, and we expect the next update to be the monthly edition on Feb 2.

For any questions, kindly contact us at support@GraycellAdvisors.com.

Sincerely,
Graycell Advisors

Graycell Advisors, and its affiliates, officers, employees, families, and all other related parties, collectively referred to as ‘Graycell’ and/or ‘we,’ is a publisher of financial information, such as the Prudent Biotech and Smallcap newsletters. Historical performance figures provided are hypothetical and unaudited, and based on our proprietary analysis and system performance, back-tested over an extended period of time. The performance results obtained are intended for illustrative purposes only. Past performance is not indicative of future results, which may vary. All stock and related investments have a degree of risk, which can result in a significant or total loss. In addition, smallcap segment is characterized by much higher risk and volatility than the general stock market. The Information contained herein does not constitute a personal recommendation or takes into account the particular investment objectives, financial situations, or needs of individual investors. If you decide to invest in any of the stocks of the companies mentioned in the newsletters, samples, alerts, etc., sent to you or available on our websites, you can and may lose some or all of your investment. You alone are responsible for your own investment decisions. We are not liable nor do we assume any responsibility for losses incurred as a result of any information provided or not provided or not made available in a timely manner, herein or on our website or using any other medium.  We also cannot guarantee the accuracy and completeness of any information furnished by us. Graycell is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. We may or may not already have existing positions in the stocks mentioned in our reports. Our models are proprietary and/or licensed and can be changed or revised based on our discretion at any time without any notification. Subscribers and investors should always conduct their own due diligence with any potential investment and consider obtaining professional advice before making an investment decision.